TRUP Trupanion Inc.

Trupanion Reports Strong Third Quarter 2025 Results and Secures New Credit Facility

Trupanion Reports Strong Third Quarter 2025 Results and Secures New Credit Facility

SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the third quarter ended September 30, 2025.

“We delivered record quarterly profitability while accelerating subscription pet growth for the third consecutive quarter,” said Margi Tooth, Chief Executive Officer and President of Trupanion. “With a strong financial foundation, we have the flexibility to invest where it matters most - driving sustainable growth and expanding access to care. Our disciplined model continues to generate meaningful cash flow, positioning us to build on this momentum in the quarters ahead.”



Third Quarter 2025 Financial and Business Highlights

  • Total revenue was $366.9 million, an increase of 12% compared to the third quarter of 2024.
  • Total enrolled pets (including pets from our other business segment) was 1,654,414 at September 30, 2025, a decrease of 2% over September 30, 2024.
  • Subscription business revenue was $252.7 million, an increase of 15% compared to the third quarter of 2024.
  • Subscription enrolled pets was 1,082,412 at September 30, 2025, an increase of 5% over September 30, 2024.
  • Net income was $5.9 million, or $0.14 per basic and $0.13 per diluted share, compared to net income of $1.4 million, or $0.03 per basic and diluted share, in the third quarter of 2024.
  • Adjusted EBITDA was $19.6 million, compared to adjusted EBITDA of $14.5 million in the third quarter of 2024.
  • Operating cash flow was $29.2 million and free cash flow was $23.9 million in the third quarter of 2025. This compared to operating cash flow of $15.3 million and free cash flow of $13.4 million in the third quarter of 2024.



First Nine Months 2025 Financial and Business Highlights

  • Total revenue was $1,062.5 million, an increase of 12% compared to the first nine months of 2024.
  • Subscription business revenue was $727.9 million, an increase of 16% compared to the first nine months of 2024.
  • Net income was $13.8 million, or $0.32 per basic and per diluted share, compared to net loss of $(11.3) million, or $(0.27) per basic and diluted share, in the first nine months of 2024.
  • Adjusted EBITDA was $48.4 million, compared to adjusted EBITDA of $26.7 million in the first nine months of 2024.
  • Operating cash flow was $60.2 million and free cash flow was $50.0 million in the first nine months of 2025. This compared to operating cash flow of $24.6 million and free cash flow of $16.7 million in the first nine months of 2024.
  • At September 30, 2025, the Company held $348.5 million in cash and short-term investments, including $58.5 million held outside the insurance entities, with an additional $15.0 million available under its credit facility.



New Credit Facility with PNC Bank

Trupanion announced today the successful completion of a debt transaction that further enhances the company’s financial flexibility and long-term growth capacity. As part of this transaction, Trupanion entered into a new credit agreement with PNC Bank, N.A., a member of the PNC Financial Services Group, Inc. (NYSE: PNC), one of the largest diversified financial services institutions in the United States. The new three-year $120 million credit facility was used to repay the prior credit facility and has a lower interest rate, which provides additional savings to support Trupanion’s strategic initiatives and operational investments.

“This new lower-cost credit facility, established with a trusted financial institution like PNC Bank, marks another important step in strengthening our capital structure,” said Fawwad Qureshi, Chief Financial Officer of Trupanion. “It provides us with greater flexibility to allocate capital toward opportunities that drive long-term shareholder value. This transaction reflects the progress we’ve made in strengthening our balance sheet over the last two years and positions us well for continued investment in sustainable growth.”

The transaction underscores Trupanion’s ongoing commitment to prudent financial management as the company continues to expand its reach across North America and beyond, helping more pets gain access to high-quality medical care when they need it most.

Conference Call

Trupanion’s management will host a conference call today to review its third quarter 2025 results. The call is scheduled to begin shortly after 1:30 p.m. PT/ 4:30 p.m. ET. A live webcast will be accessible through the Investor Relations section of Trupanion’s website at / and will be archived online for 3 months upon completion of the conference call. Participants can access the conference call by dialing 1-844-676-1342 (United States) or 1-412-634-6683 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 10203296.

About Trupanion

Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe with over 1,000,000 pets currently enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet parents with the highest value in pet medical insurance with unlimited payouts for the life of their pets. With its patented process, Trupanion is the only North American provider with the technology to pay veterinarians directly in seconds at the time of checkout. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company or ZPIC Insurance Company and, in Canada, by Accelerant Insurance Company of Canada or GPIC Insurance Company. Policies are sold and administered in Canada by Canada Pet Health Insurance Services, Inc. dba Trupanion 309-1277 Lynn Valley Road, North Vancouver, BC V7J 0A2 and in the United States by Trupanion Managers USA, Inc. (CA license No. 0G22803, NPN 9588590). Canada Pet Health Insurance Services, Inc. is a registered damage insurance agency and claims adjuster in Quebec #603927. For more information, please visit trupanion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to, among other things, expectations, plans, prospects and financial results for Trupanion, including, but not limited to, its expectations regarding its ability to continue to grow its enrollments and revenue, and otherwise execute its business plan. These forward-looking statements are based upon the current expectations and beliefs of Trupanion’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements made in this press release are based on information available to Trupanion as of the date hereof, and Trupanion has no obligation to update these forward-looking statements.

In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods; the ability to keep growing our membership base and revenue; the accuracy of assumptions used in determining appropriate member acquisition expenditures; the severity and frequency of claims; the ability to maintain high retention rates; the accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency; actual claims expense exceeding estimates; regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense; the effectiveness and statutory or regulatory compliance of our Territory Partner model and of our Territory Partners, veterinarians and other third parties in recommending medical plan subscriptions to potential members; the ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals; compliance by us and those referring us members with laws and regulations that apply to our business, including the sale of a pet medical plan; the ability to maintain the security of our data; fluctuations in the Canadian currency exchange rate; the ability to protect our proprietary and member information; the ability to maintain our culture and team; the ability to maintain the requisite amount of risk-based capital; our ability to generate sufficient cash flows to repay or otherwise comply with requirements of our outstanding debt; our ability to implement and maintain effective controls, including to remediate material weaknesses in internal controls over financial reporting; the ability to protect and enforce Trupanion’s intellectual property rights; the ability to successfully implement our alliance with Aflac; our ability to successfully finalize the transition of policies from Accelerant to our wholly owned subsidiary, GPIC; the ability to continue key contractual relationships with third parties; third-party claims including litigation and regulatory actions; the ability to recognize benefits from investments in new solutions and enhancements to Trupanion’s technology platform and website; our ability to retain key personnel; and deliberations and determinations by the Trupanion board based on the future performance of the company or otherwise.

For a detailed discussion of these and other cautionary statements, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion’s Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequently filed reports on Forms 10-Q, 10-K and 8-K. All documents are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system at or the Investor Relations section of Trupanion’s website at

Non-GAAP Financial Measures

Trupanion’s stated results may include certain non-GAAP financial measures. These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in its industry as other companies in its industry may calculate or use non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Trupanion’s reported financial results. The presentation and utilization of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Trupanion urges its investors to review the reconciliation of its non-GAAP financial measures to the most directly comparable GAAP financial measures in its consolidated financial statements, and not to rely on any single financial or operating measure to evaluate its business. These reconciliations are included below and on Trupanion’s Investor Relations website.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, Trupanion believes that providing various non-GAAP financial measures that exclude stock-based compensation expense and depreciation and amortization expense allows for more meaningful comparisons between its operating results from period to period. Trupanion offsets new pet acquisition expense with sign-up fee revenue in the calculation of net acquisition cost because it collects sign-up fee revenue from new members at the time of enrollment and considers it to be an offset to a portion of Trupanion’s new pet acquisition expense. Trupanion believes this allows it to calculate and present financial measures in a consistent manner across periods. Trupanion’s management believes that the non-GAAP financial measures and the related financial measures derived from them are important tools for financial and operational decision-making and for evaluating operating results over different periods of time.

Trupanion, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share data)
 Three Months Ended September 30, Nine Months Ended September 30,
  2025   2024   2025   2024 
 (unaudited)
Revenue:       
Subscription business$252,697  $218,986  $727,917  $628,738 
Other business 114,223   108,470   334,535   319,639 
Total revenue 366,920   327,456   1,062,452   948,377 
Cost of revenue:       
Subscription business 200,766   177,365   586,098   525,237 
Other business 106,100   100,712   310,370   297,265 
Total cost of revenue(1), (2) 306,866   278,077   896,468   822,502 
Operating expenses:       
Technology and development(1) 9,887   7,933   26,545   23,083 
General and administrative(1) 18,311   16,977   58,325   46,903 
New pet acquisition expense(1) 21,946   18,308   62,305   53,025 
Depreciation and amortization 4,051   4,381   11,804   12,542 
Total operating expenses 54,195   47,599   158,979   135,553 
Loss from investment in joint venture    (34)  (305)  (184)
Operating income (loss) 5,859   1,746   6,700   (9,862)
Interest expense 2,790   3,820   9,683   11,071 
Other (income), net (3,530)  (3,538)  (18,684)  (9,601)
Income (loss) before income taxes 6,599   1,464   15,701   (11,332)
Income tax (benefit) expense 726   39   1,898   (43)
Net income (loss)$5,873  $1,425  $13,803  $(11,289)
        
Net income (loss) per share:       
Basic$0.14  $0.03  $0.32  $(0.27)
Diluted$0.13  $0.03  $0.32  $(0.27)
Weighted average shares of common stock outstanding:       
Basic 43,076,695   42,233,903   42,849,769   42,076,998 
Diluted 43,562,132   42,822,505   43,550,326   42,076,998 
        
(1)Includes stock-based compensation expense as follows:

Three Months Ended September 30,

 Nine Months Ended September 30,
  2025   2024   2025   2024 
Veterinary invoice expense$677  $847  $2,221  $2,625 
Other cost of revenue 585   554   1,679   1,561 
Technology and development 1,705   1,259   4,326   3,774 
General and administrative 4,971   4,125   14,546   11,435 
New pet acquisition expense 1,561   1,555   6,013   5,743 
Total stock-based compensation expense$9,499  $8,340  $28,785  $25,138 
        
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:
 Three Months Ended September 30, Nine Months Ended September 30,
  2025   2024   2025   2024 
Veterinary invoice expense$263,127  $238,814  $766,157  $703,485 
Other cost of revenue 43,739   39,263   130,311   119,017 
Total cost of revenue$306,866  $278,077  $896,468  $822,502 



 
Trupanion, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share data)
 September 30, 2025 December 31, 2024
 (unaudited)  
Assets   
Current assets:   
Cash and cash equivalents$154,773  $160,295 
Short-term investments 193,761   147,089 
Accounts and other receivables, net of allowance for credit losses of $1,595 at September 30, 2025 and $1,117 at December 31, 2024 302,534   274,031 
Prepaid expenses and other assets 16,963   15,912 
Total current assets 668,031   597,327 
Restricted cash 34,136   39,235 
Long-term investments 981   373 
Property, equipment, and internal-use software, net 104,683   102,191 
Intangible assets, net 24,772   13,177 
Other long-term assets 7,186   17,579 
Goodwill 40,384   36,971 
Total assets$880,173  $806,853 
Liabilities and stockholders’ equity   
Current liabilities:   
Accounts payable$12,760  $11,532 
Accrued liabilities and other current liabilities 43,577   33,469 
Reserve for veterinary invoices 53,972   51,635 
Deferred revenue 279,713   251,640 
Long-term debt - current portion 750   1,350 
Total current liabilities 390,772   349,626 
Long-term debt 113,790   127,537 
Deferred tax liabilities 2,252   1,946 
Other liabilities 4,797   4,476 
Total liabilities 511,611   483,585 
Stockholders’ equity:   
Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 44,220,625 and 43,192,339 issued and outstanding at September 30, 2025; 43,516,631 and 42,488,445 shares issued and outstanding at December 31, 2024     
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding     
Additional paid-in capital 595,802   568,302 
Accumulated other comprehensive income (loss) 1,379   (2,612)
Accumulated deficit (212,085)  (225,888)
Treasury stock, at cost: 1,028,186 shares at September 30, 2025 and December 31, 2024 (16,534)  (16,534)
Total stockholders’ equity 368,562   323,268 
Total liabilities and stockholders’ equity$880,173  $806,853 



 
Trupanion, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)
 Three Months Ended September 30, Nine Months Ended September 30,
  2025   2024   2025   2024 
 (unaudited)
Operating activities       
Net income (loss)$5,873  $1,425  $13,803  $(11,289)
Adjustments to reconcile net income (loss) to cash provided by operating activities:       
Depreciation and amortization 4,051   4,381   11,804   12,542 
Stock-based compensation expense 9,499   8,341   28,785   25,138 
Realized gain on nonmonetary exchange of preferred stock investment       (7,783)   
Other, net 215   (136)  1,164   (453)
Changes in operating assets and liabilities:       
Accounts and other receivables (9,912)  (3,794)  (27,927)  (22,020)
Prepaid expenses and other assets 44   101   (540)  2,398 
Accounts payable, accrued liabilities, and other liabilities 10,026   1,377   11,017   (350)
Reserve for veterinary invoices 1,538   (3,934)  2,235   (6,469)
Deferred revenue 7,904   7,535   27,668   25,088 
Net cash provided by operating activities 29,238   15,296   60,226   24,585 
Investing activities       
Purchases of investment securities (41,020)  (26,125)  (183,021)  (107,375)
Maturities and sales of investment securities 43,563   26,089   137,827   81,767 
Purchases of property, equipment, and internal-use software (5,302)  (1,914)  (10,206)  (7,858)
Other 437   490   1,639   1,552 
Net cash used in investing activities (2,322)  (1,460)  (53,761)  (31,914)
Financing activities       
Repayment of debt financing (188)  (338)  (15,713)  (1,013)
Proceeds from exercise of stock options 80   258   1,407   729 
Shares withheld to satisfy tax withholding (1,179)  (802)  (2,867)  (1,390)
Other (154)  (157)  (614)  (609)
Net cash used in financing activities (1,441)  (1,039)  (17,787)  (2,283)
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net (1,037)  481   701   19 
Net change in cash, cash equivalents, and restricted cash 24,438   13,278   (10,621)  (9,593)
Cash, cash equivalents, and restricted cash at beginning of period 164,471   147,593   199,530   170,464 
Cash, cash equivalents, and restricted cash at end of period$188,909  $160,871  $188,909  $160,871 



 
The following tables set forth our key operating metrics.
                
 Nine Months Ended

September 30,
            
 2025 2024            
Total Business:               
Total pets enrolled (at period end) 1,654,414   1,688,903             
Subscription Business:               
Total subscription pets enrolled (at period end) 1,082,412   1,032,042             
Monthly average revenue per pet$79.84  $71.94             
Average pet acquisition cost (PAC)$278  $227             
Average monthly retention 98.33%  98.29%            
                
                
 Three Months Ended
 Sep. 30, 2025 Jun. 30, 2025 Mar. 31, 2025 Dec. 31, 2024 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023
Total Business:               
Total pets enrolled (at period end) 1,654,414   1,660,455   1,667,637   1,677,570   1,688,903   1,699,643   1,708,017   1,714,473 
Subscription Business:               
Total subscription pets enrolled (at period end) 1,082,412   1,066,354   1,052,845   1,041,212   1,032,042   1,020,934   1,006,168   991,426 
Monthly average revenue per pet$82.01  $79.93  $77.53  $76.02  $74.27  $71.72  $69.79  $67.07 
Average pet acquisition cost (PAC)$290  $276  $267  $261  $243  $231  $207  $217 
Average monthly retention 98.33%  98.29%  98.28%  98.25%  98.29%  98.34%  98.41%  98.49%



The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands):
        
 Three Months Ended September 30, Nine Months Ended September 30,
  2025   2024   2025   2024 
Net cash provided by operating activities$29,238  $15,296  $60,226  $24,585 
Purchases of property, equipment, and internal-use software (5,302)  (1,914)  (10,206)  (7,858)
Free cash flow$23,936  $13,382  $50,020  $16,727 



The following tables reflect the reconciliation between GAAP and non-GAAP measures (in thousands except percentages):
  Three Months Ended September 30, Nine Months Ended September 30,
  2025 2024 2025 2024
Veterinary invoice expense $263,127  $238,814  $766,157  $703,485 
Less:        
Stock-based compensation expense(1)  (666)  (830)  (2,188)  (2,535)
Other business cost of paying veterinary invoices(2)  (85,394)  (82,507)  (247,369)  (239,342)
Subscription cost of paying veterinary invoices (non-GAAP) $177,067  $155,477  $516,600  $461,608 
% of subscription revenue  70.1%  71.0%  71.0%  73.4%
         
Other cost of revenue $43,739  $39,263  $130,311  $119,017 
Less:        
Stock-based compensation expense(1)  (579)  (536)  (1,661)  (1,479)
Other business variable expenses(2)  (20,702)  (18,126)  (62,969)  (57,713)
Subscription variable expenses (non-GAAP) $22,458  $20,601  $65,681  $59,825 
% of subscription revenue  8.9%  9.4%  9.0%  9.5%
         
Technology and development expense $9,887  $7,933  $26,545  $23,083 
General and administrative expense  18,311   16,977   58,325   46,903 
Less:        
Stock-based compensation expense(1)  (6,551)  (5,258)  (18,340)  (14,465)
Development expenses(3)  (1,199)  (1,474)  (3,551)  (4,307)
Fixed expenses (non-GAAP) $20,448  $18,178  $62,979  $51,214 
% of total revenue  5.6%  5.6%  5.9%  5.4%
         
New pet acquisition expense $21,946  $18,308  $62,305  $53,025 
Less:        
Stock-based compensation expense(1)  (1,527)  (1,503)  (5,916)  (5,426)
Other business pet acquisition expense(2)  (5)  (8)  (82)  (31)
Subscription acquisition cost (non-GAAP) $20,414  $16,797  $56,307  $47,568 
% of subscription revenue  8.1%  7.7%  7.7%  7.6%
(1)Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million and $0.7 million for the three and nine months ended September 30, 2025, respectively.

(2)Excludes the portion of stock-based compensation expense attributable to the other business segment

(3)Consists of costs related to product exploration and development that are pre-revenue and historically have been insignificant.



The following tables reflect the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages):
 Three Months Ended September 30, Nine Months Ended September 30,
  2025   2024   2025   2024 
Operating income (loss)$5,859  $1,746  $6,700  $(9,862)
Non-GAAP expense adjustments       
Acquisition cost 20,419   16,805   56,389   47,599 
Stock-based compensation expense(1) 9,323   8,127   28,105   23,905 
Development expenses(2) 1,199   1,474   3,551   4,307 
Depreciation and amortization 4,051   4,381   11,804   12,542 
Loss from investment in joint venture    (34)  (305)  (184)
Total adjusted operating income (non-GAAP)$40,851  $32,567  $106,854  $78,675 
        
Subscription Business:       
Subscription operating income (loss)$7,826  $3,824  $13,410  $(4,109)
Non-GAAP expense adjustments       
Acquisition cost 20,414   16,797   56,307   47,568 
Stock-based compensation expense(1) 7,234   6,215   22,250   18,723 
Development expenses(2) 826   986   2,433   2,855 
Depreciation and amortization 2,790   2,929   8,087   8,315 
Subscription adjusted operating income (non-GAAP)$39,090  $30,751  $102,487  $73,352 
        
Other Business:       
Other business operating loss$(1,967) $(2,044) $(6,405) $(5,569)
Non-GAAP expense adjustments       
Acquisition cost 5   8   82   31 
Stock-based compensation expense(1) 2,089   1,912   5,855   5,182 
Development expenses(2) 373   488   1,118   1,452 
Depreciation and amortization 1,261   1,452   3,717   4,227 
Other business adjusted operating income (non-GAAP)$1,761  $1,816  $4,367  $5,323 
(1)Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation in accordance with GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million and $0.7 million for the three and nine months ended September 30, 2025, respectively.
(2)Consists of costs related to product exploration and development that are pre-revenue and historically have been insignificant.



The following tables reflect the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages):
  Three Months Ended September 30,

 Nine Months Ended September 30,
  2025 2024 2025 2024
Subscription revenue $252,697  $218,986  $727,917  $628,738 
Subscription cost of paying veterinary invoices  177,067   155,477   516,600   461,608 
Subscription variable expenses  22,458   20,601   65,681   59,825 
Subscription fixed expenses*  14,082   12,157   43,149   33,953 
Subscription adjusted operating income (non-GAAP) $39,090  $30,751  $102,487  $73,352 
         
Other business revenue $114,223   108,470  $334,535  $319,639 
Other business cost of paying veterinary invoices  85,394   82,507   247,369   239,342 
Other business variable expenses  20,702   18,126   62,969   57,713 
Other business fixed expenses*  6,366   6,021   19,830   17,261 
Other business adjusted operating income (non-GAAP) $1,761  $1,816  $4,367  $5,323 
         
Revenue $366,920  $327,456  $1,062,452  $948,377 
Cost of paying veterinary invoices  262,461   237,984   763,969   700,950 
Variable expenses  43,160   38,727   128,650   117,538 
Fixed expenses*  20,448   18,178   62,979   51,214 
Total business adjusted operating income (non-GAAP) $40,851  $32,567  $106,854  $78,675 
         
As a percentage of revenue: Three Months Ended September 30, Nine Months Ended September 30,
  2025 2024 2025 2024
Subscription revenue  100.0%  100.0%  100.0%  100.0%
Subscription cost of paying veterinary invoices  70.1%  71.0%  71.0%  73.4%
Subscription variable expenses  8.9%  9.4%  9.0%  9.5%
Subscription fixed expenses*  5.6%  5.6%  5.9%  5.4%
Subscription adjusted operating income (non-GAAP)  15.5%  14.0%  14.1%  11.7%
         
Other business revenue  100.0%  100.0%  100.0%  100.0%
Other business cost of paying veterinary invoices  74.8%  76.1%  73.9%  74.9%
Other business variable expenses  18.1%  16.7%  18.8%  18.1%
Other business fixed expenses*  5.6%  5.6%  5.9%  5.4%
Other business adjusted operating income (non-GAAP)  1.5%  1.7%  1.3%  1.7%
         
Revenue  100.0%  100.0%  100.0%  100.0%
Cost of paying veterinary invoices  71.5%  72.7%  71.9%  73.9%
Variable expenses  11.8%  11.8%  12.1%  12.4%
Fixed expenses*  5.6%  5.6%  5.9%  5.4%
Total business adjusted operating income (non-GAAP)  11.1%  9.9%  10.1%  8.3%
         
*Fixed expenses represent shared services that support both our subscription and other business segments and, as such, are generally allocated to each segment pro-rata based on revenues.



Adjusted operating income is a non-GAAP financial measure that adjusts operating income (loss) to remove the effect of acquisition cost, development expenses, and gain (loss) from investment in joint venture. Non-cash items, such as stock-based compensation expense and depreciation and amortization, are also excluded. Acquisition cost, development expenses, gain (loss) from investment in joint venture, stock-based compensation expense, and depreciation and amortization are expected to remain recurring expenses for the foreseeable future, but are excluded from this metric to measure scale in other areas of the business. Management believes acquisition costs primarily represent the cost to acquire new subscribers and are driven by the amount of growth we choose to pursue based primarily on the amount of our adjusted operating income period over period. Accordingly, this measure is not indicative of our core operating income performance. We also exclude development expenses, gain (loss) from investment in joint venture, stock-based compensation expense, and depreciation and amortization because we do not view those items as reflective of our core operating income performance.

Management uses adjusted operating income and the margin on adjusted operating income to understand the effects of scale in its non-acquisition cost and development expenses and to plan future advertising expenditures, which are designed to acquire new pets. Management uses this measure as a principal way of understanding the operating performance of its business exclusive of acquisition cost and new product exploration and development initiatives.  Management believes disclosure of this metric provides investors with the same data that the Company employs in assessing its overall operations and that disclosure of this measure may provide useful information regarding the efficiency of our utilization of revenues, return on advertising dollars in the form of new subscribers and future use of available cash to support the continued growth of our business.

The following tables reflect the reconciliation of adjusted EBITDA to net income (loss) (in thousands):
                
 Nine Months Ended September 30,            
  2025   2024             
Net income (loss)$13,803  $(11,289)            
Excluding:               
Stock-based compensation expense(1) 28,105   23,906             
Depreciation and amortization expense 11,804   12,542             
Interest income (9,141)  (9,412)            
Interest expense 9,683   11,071             
Income tax (benefit) expense 1,898   (43)            
Loss from equity method investment    (33)            
Realized gain on nonmonetary exchange of preferred stock investment (7,783)               
Adjusted EBITDA$48,369  $26,742             
                
 Three Months Ended
 Sep. 30, 2025 Jun. 30, 2025 Mar. 31, 2025 Dec. 31, 2024 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023
Net income (loss)$5,873  $9,413  $(1,483) $1,656  $1,425  $(5,862) $(6,852) $(2,163)
Excluding:               
Stock-based compensation expense(1) 9,323   9,268   9,514   8,036   8,127   8,381   7,398   6,636 
Depreciation and amortization expense 4,051   3,962   3,791   3,924   4,381   4,376   3,785   3,029 
Interest income (3,201)  (3,105)  (2,835)  (2,999)  (3,232)  (3,135)  (3,045)  (2,842)
Interest expense 2,790   3,682   3,211   3,427   3,820   3,655   3,596   3,697 
Income tax (benefit) expense 726   1,133   39   38   39   (44)  (38)  130 
Goodwill impairment charges          5,299             
Loss from equity method investment             (33)         
Realized gain on nonmonetary exchange of preferred stock investment    (7,783)                  
Adjusted EBITDA$19,562  $16,570  $12,237  $19,381  $14,527  $7,371  $4,844  $8,487 
(1)Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million and $0.7 million for the three and nine months ended September 30, 2025, respectively.



Contacts:

Investors:

Laura Bainbridge, Senior Vice President, Corporate Communications

Gil Melchior, Director, Investor Relations

A figure accompanying this announcement is available at



EN
06/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trupanion Inc.

 PRESS RELEASE

Trupanion Reports Strong Third Quarter 2025 Results and Secures New Cr...

Trupanion Reports Strong Third Quarter 2025 Results and Secures New Credit Facility SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the third quarter ended September 30, 2025. “We delivered record quarterly profitability while accelerating subscription pet growth for the third consecutive quarter,” said Margi Tooth, Chief Executive Officer and President of Trupanion. “With a strong financial foundation, we have the flexibility to invest where it matters most - drivi...

 PRESS RELEASE

BMO Insurance and Trupanion Join Forces to Bring Simple, Trusted Pet I...

BMO Insurance and Trupanion Join Forces to Bring Simple, Trusted Pet Insurance to More Canadians TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BMO Insurance and Trupanion, the leading provider of medical insurance for cats and dogs in Canada, are partnering to expand access to trusted, high-quality pet health coverage for Canadian pet owners. According to the latest BMO Real Financial Progress Index, nearly four-in-five Canadians (79%) consider their pets to be full members of their family. However, despite pet owners deep love for their animals, only about 4 per cent of Canadian pets have ...

 PRESS RELEASE

Trupanion Appoints Bradley Powell to Board of Directors

Trupanion Appoints Bradley Powell to Board of Directors SEATTLE, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), a leader in medical insurance for cats and dogs, announced today the appointment of Bradley Powell, former Chief Financial Officer of Expeditors International of Washington, to the Company’s Board of Directors. “We are delighted to welcome Brad to our Board of Directors,” said Margi Tooth, Chief Executive Officer and President of Trupanion. “His long tenure as CFO of Expeditors, a company with a fantastic long-term track record, gives him a deep understanding...

 PRESS RELEASE

Trupanion Publishes 2025 Corporate Social Responsibility Report

Trupanion Publishes 2025 Corporate Social Responsibility Report Trupanion shares insights into corporate governance, commitment to sustainability, and more in their latest Corporate Social Responsibility Report SEATTLE, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), a leader in medical insurance for cats and dogs, announced today that they have published their fifth corporate social responsibility report. The report is now available on Trupanion’s Investor Relations website . About Trupanion Trupanion is a leader in medical insurance for cats and dogs throughout...

 PRESS RELEASE

Ready for the Spotlight: Trupanion Announces 2025 truFame Winners

Ready for the Spotlight: Trupanion Announces 2025 truFame Winners Seven dogs and three cats from across North America will be the new faces of Trupanion SEATTLE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Meet Atlas, a beautiful Siberian Husky from Ontario, Canada. Today Trupanion is proud to announce that Atlas is a truFame winner, one of ten pets chosen to be the faces of Trupanion in 2026. Just last year, however, Atlas’ family received far different news. Atlas, who wasn’t even two years old at the time, needed two emergency surgeries in less than eight months. Luckily, Atlas had Trupanion ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch